Sepmag wins Chinese Patent

Sepmag, manufacturer of world leading biomagnetic separation systems for the in vitro diagnostics market, has received a Chinese patent for the Company’s homogenous magnetophoresis technology – issued by China’s State Intellectual Property Office (SIPO).

Shipping has already commenced of the Sepmag Q250ml to CapitalBio, its first client in the region, for the processing of large batch volumes in protein purification. Following the success of this contract, Sepmag intends to actively market itself to dignostic companies across China looking for an alternative to traditional technologies like Enzyme-Linked ImmunoSorbent Assays (ELISA). The magnetophoresis system produces a completely homogeneous magnetic field, applying the same magnetic force on beads regardless of the distance from the magnetic ring. This is said to reduce the variability of the end product, enable a more straightforward scale-up process and simplify revalidation processes .

Josep Maria Simó, CEO of Sepmag, commented: “We are delighted that the Chinese Patent Office has granted Sepmag a patent for our unique magnetophoresis techniques. This will allow us to further consolidate our Far-East presence, having already established a strong and growing foothold in Japan. Over the next couple of years, we forecast the Chinese marketplace to be amongst the fastest growing for biomagnetic separation systems.

The agreement we have signed with CapitalBio marks the start of a significant expansion in the region and a continuation of the internationalisation of Sepmag technologies.”